Key result
Modern non-invasive cardiovascular imaging techniques, including MSCT and 18F-FDG PET, are essential for assessing the risk and diagnosing cardiovascular toxicity of antitumor therapy.
Why the study?
Assessing the risk and diagnosing cardiovascular toxicity of antitumor therapy is a key component of cardio-oncology that relies heavily on cardiovascular imaging.
Design
Review
Authors
Loading...
May inform imaging-based cardiotoxicity monitoring per 2022 ESC guidelines; leaves open prospective validation of emerging techniques.
This review highlights current and emerging non-invasive imaging techniques for diagnosing and assessing the risk of cardiovascular toxicity in patients undergoing antitumor therapy.
Belenkov et al. (2024) conducted a review in Cardiovascular toxicity of antitumor therapy. Cardiovascular imaging techniques was evaluated. Modern non-invasive cardiovascular imaging techniques, including MSCT and 18F-FDG PET, are essential for assessing the risk and diagnosing cardiovascular toxicity of antitumor therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: